CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 801–900 of 1,725
A Snapshot of the Most Recent Transthyretin Stabilizers
Marotta, C., Ciccone, L., Orlandini, E., Rossello, A., & Nencetti, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189969 · Cited by 10
“This strategy involves the introduction of breaks into the double-strand DNA and its consequent editing for a selective knock-down of TTR expression [80–84].”
BackgroundMiddlezong, W., Stinnett, V., Phan, M., Phan, B., Morsberger, L. A., Klausner, M., Ghabrial, J., DeMetrick, N., Zhu, J., James, T., et al. (2024) · Biomolecules · doi:10.3390/biom14121595 · Cited by 10
Target product profile for cell-based and gene-based therapies to achieve a cure for HIV
Lewin, S. R., Bansbach, C., Kemps, D., Mathae, L., Das, K. T., McCune, J. M., Deeks, S. G., & Ndung'u, T. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00277-7 · Cited by 9
Su, W.-C., Lieu, R., Fu, Y., Kempen, T. J., Yu, Z., Zhang, K., Chen, T., & Fan, Y. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465788 · Cited by 11
TOPO-seq reveals DNA topology-induced off-target activity by Cas9 and base editors
Duan, M., Gao, P., Zhang, Y.-Z., Hu, Y.-L., Zhou, L., Xu, Z.-C., Qiu, H.-Y., Tong, X., Ji, R.-J., Lei, X.-L., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01867-7 · Cited by 9
Gene Editing in Ganoderma lucidum: Development, Challenges, and Future Prospects
He, S., Liu, Y., Zhang, Z., Cai, M., Hao, Y., & Hu, H. (2025) · Journal of Fungi · doi:10.3390/jof11040310 · Cited by 11
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 12
“The feasibility of this approach has been demonstrated in a clinical trial targeting the liver for the treatment of transthyretin amyloidosis 73 .”
Kimura, S., Okada, K., Matsubara, N., Lyu, F., Tsutsumi, S., Kimura, Y., Hashiya, F., Inagaki, M., Abe, N., & Abe, H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00084j · Cited by 17
“11 However, nucleic acid molecules, including mRNA, inherently face challenges due to their negative charge, which limits membrane permeability, as well as their susceptibility to enzymatic degradation.”
Focused ultrasound‐mediated APOE4 knockdown in mouse brain
Zheng, K., Tsitsos, F. N., Batts, A. J., Ji, R., Nuriel, T., Konofagou, E. E., & Leong, K. W. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70464 · Cited by 8
“70 Neverthe-less, the synthesized nanomaterials are usually larger than the 25 nm AAVs, 71,72 requiring further optimization of FUS parameters to ensure effective brain-wide delivery.”
Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A
Zhao, J.-J., Tian, S.-N., Peng, Z.-Y., Ren, J., Zhang, Y., Li, G., Deng, D.-H., Zhang, J., & Zhang, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114141 · Cited by 13
Noncanonical target-strand cytosine base editing via engineered Un1Cas12f1 platform
Song, Z., Guo, J., Fan, Z., Huang, S., Li, G., Zhao, Z., Chen, B., Huang, S., Zheng, W., Wei, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64562-0 · Cited by 12
“Previously, in vivo genome editing-dependent knockdown of TTR gene was developed as a promising treatment strategy for transthyretinamyloidosis 35,36 .”
Polyester materials for mRNA delivery
Chen, W., Ma, Y., Liu, X., & Zhu, D. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00075 · Cited by 9
Law, S., Arnold, J., Rauf, M. U., Heptinstall, L., Gilbertson, J. A., Rowczenio, D. M., Baharani, J., Langman, G., Fontana, M., & Gillmore, J. D. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.08.018 · Cited by 9
“Treatment of ATTRv amyloidosis has been revolutionized in recent years by development of TTR stabilizers such as tafamidis, RNA-targeted therapies such as patisiran and inotersen (along with their second-generation counterparts vutrisiran and eplontersen, respectively), and novel in vivo gene editing therapeutics.(16)…”
BackgroundSelf-citationLi, S., Du, M., Deng, J., Deng, G., Li, J., Song, Z., & Han, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.015 · Cited by 10
Constructing next-generation CRISPR–Cas tools from structural blueprints
Bravo, J. P. K., Hibshman, G. N., & Taylor, D. W. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102839 · Cited by 8
Gene therapy review: Duchenne muscular dystrophy case study
Berling, É., Nicolle, R., Laforêt, P., & Ronzitti, G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.11.005 · Cited by 11
Lohchania, B., Christopher, A. C., Arjunan, P., Mahalingam, G., Kathirvelu, D., Prasannan, A., Venkatesan, V., Taneja, P., Mohankumar, K. M., Thangavel, S., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1031049 · Cited by 10
“successfully edited the transthyretin (TTR) gene in the adult human liver for treating human hereditary transthyretin (hATTR) amyloidosis by intravenously injecting lipid nanoparticles encapsulating Cas9 mRNA and TTR gene targeting single guide RNA (sgRNA) (Batista and Flotte, 2021; Gillmore et al., 2021).”
BackgroundBiodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
Puccetti, M., Schoubben, A., Giovagnoli, S., & Ricci, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032218 · Cited by 12
“The safety of the treatment was found to be very satisfactory, since only a few and very mild adverse effects occurred in analyzed patients [16].”
BackgroundDöbler, N. A., & Carbon, C. (2023) · Integrative Psychological and Behavioral Science · doi:10.1007/s12124-023-09797-6 · Cited by 14
“While CRISPR is already in use for therapeutic reasons (Gillmore et al., 2021; Khalaf et al., 2020), the application of this technology to edit the genome of two twins to prevent infection with HIV sparked worldwide outrage (Almeida & Diogo, 2019; Cyranoski & Ledford, 2018; Wang et al., 2018).”
BackgroundEvmenov, K., Pustogarov, N., Panteleev, D. Y., Safin, A., & Alkalaeva, E. Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031622 · Cited by 10
“This technology has been successfully applied in both in vitro and in vivo studies [4,5].”
MethodBolduc, V., Sizov, K., Brull, A., Esposito, E., Chen, G. S., Uapinyoying, P., Sarathy, A., Johnson, K. R., & Bönnemann, C. G. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102269 · Cited by 11
“51 In these trials, expression levels of the targeted genes were strongly reduced; however, the gRNAs were designed to target both alleles.”
Determination of Factors Driving the Genome Editing Field in the CRISPR Era Using Bibliometrics
Huang, Y., Zhang, Y., Wu, M., Porter, A. L., & Barrangou, R. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.0001 · Cited by 10
“10,11 These tipping points triggered by specific publications and technology development define distinct time periods that provide useful to assess the dynamic evolution of the field.”
Hall, B., Alonzo, M., Texter, K. M., Garg, V., & Zhao, M. (2022) · Birth Defects Research · doi:10.1002/bdr2.1989 · Cited by 10
Gene Edited T Cell Therapies for Inborn Errors of Immunity
Fox, T. A., Houghton, B. C., & Booth, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.899294 · Cited by 9
“Successful in vivo gene editing has recently been achieved in humans for transthyretin amyloidosis (Gillmore et al., 2021).”
BackgroundTransthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
Smiley, D. A., Rodríguez, C. M., & Maurer, M. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.06.008 · Cited by 7
CRISPR/Cas9 gene editing: A new hope for transthyretin amyloidosis treatment
Shahzad, F., Rehman, M. E. U., Basit, J., Saeed, S., Abbas, K., & Farhan, M. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104784 · Cited by 13
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses
Fachel, F. N. S., Frâncio, L., Poletto, É., Schuh, R. S., Teixeira, H. F., Giugliani, R., Baldo, G., & Matte, Ú. D. S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114616 · Cited by 10
Peña, L. D. M., Burrage, L. C., Enns, G. M., Esplin, E. D., Harding, C. O., Mendell, J. R., Niu, Z., Scharfe, C., Yu, T. W., & Koeberl, D. D. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100831 · Cited by 8
Prevalence estimation of ATTRv in China based on genetic databases
Yongsheng, Z., Chong, S., Liu, B., Hu, J., Haofeng, C., Chongbo, Z., Zhang, V. W., & Jie, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1126836 · Cited by 9
“Specifically, these benefits are better received when ATTRv is diagnosed at an early stage of disease (Benson et al., 2018; Lamb and Deeks, 2019; Adams et al., 2021b; Gillmore et al., 2021).”
BackgroundTransformative Materials for Interfacial Drug Delivery
Desai, P. B., Dasgupta, A., Sofias, A. M., Peña, Q., Göstl, R., Slabu, I., Schwaneberg, U., Stiehl, T., Wagner, W., Jockenhoevel, S., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301062 · Cited by 10
Strnad, P., & Martín, J. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2239707 · Cited by 9
“Several of them are caused by species produced by the liver, and include alpha-1 antitrypsin deficiency (AATD) and hereditary transthyretin amyloidosis (ATTR).”
MethodInfluentialChoi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B., & Lee, J. (2023) · eLife · doi:10.7554/elife.89782 · Cited by 36
“For example, CRISPR- Cas9-based editing approaches have revolutionized the investigation of genes of interest and also have begun to be applied to humans to treat diseases ( Doudna and Charpentier, 2014 ; Hsu et al., 2014 ; Stadtmauer et al., 2020 ; Gillmore et al., 2021 ; Wang et al., 2021 ).”
BackgroundA Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery
Song, S., Baek, J., & Seo, S. (2025) · Scientific Data · doi:10.1038/s41597-025-06456-w · Cited by 14
Brailovsky, Y., Rajapreyar, I., & Álvarez, R. F. E. (2023) · JACC Case Reports · doi:10.1016/j.jaccas.2023.101759 · Cited by 7
Zhou, J., Li, Y., Geng, J., Zhou, H., Liu, L., & Peng, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001478 · Cited by 10
“Gillmore et al 103 found that a single dose of NTLA-2001 (an in vivo gene-editing therapy) led to a continued reduction in serum TTR protein concentration by targeting TTR knockout.”
BackgroundRecent advances in genome engineering by CRISPR technology
Lee, Y., Oh, Y., & Lee, S. H. (2024) · BMB Reports · doi:10.5483/bmbrep.2023-0157 · Cited by 11
“Owing to these characteristics, CRISPR has recently been widely applied in various fields such as generation of transgenic animals or plants (6), characterization of genes, and development of therapeutic biomaterials (7, 8).”
BackgroundSiraj, N., Dilfy, S. H., & Abduljaleel, R. H. (2023) · Trends in Pharmaceutical Biotechnology · doi:10.57238/tpb.2023.144271.1002 · Cited by 10
“The delivery mechanisms for this treatment consist of proprietary LNPs and AAVs [78].”
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
Zhang, Z., Zhang, S., Wong, H. T., Li, D., & Feng, B. (2024) · BioDrugs · doi:10.1007/s40259-024-00654-5 · Cited by 11
“NTLA-2001 and NTLA-2002 were devised as remedies for transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE) by disrupting the TTR and KLKB1 genes, respectively [120, 121] (Fig.”
Mazahir, F., Alam, M. I., & Yadav, A. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102318 · Cited by 10
Therapeutic Gene Editing in Dyslipidemias
Zadeh, S. S. T., & Shapiro, M. D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508286 · Cited by 8
“For instance, the use of NTLA-2001, a gene editing-based therapeutic, significantly slowed the progression of transthyretin amyloidosis in six patients [10].”
MethodStructural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis
Chakrabartty, A. (2024) · Pharmaceuticals · doi:10.3390/ph17091225 · Cited by 9
Marsiglia, J. D. C., Vaalavirta, K., Knight, E., Nakamura, M., Cong, L., & Hughes, N. W. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100882 · Cited by 9
“6,7,46,47 Here, we demonstrate an integrated computational and experimental platform that can generate protein candidates and simultaneously measure on-and off-target editing activity for 10,000 ormorevariants atonce.”
Tsukamoto, T., Mizuta, H., Sakai, E., Sakurai, F., & Mizuguchi, H. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.029 · Cited by 8
Transthyretin variants impact blood–nerve barrier and neuroinflammation in amyloidotic neuropathy
Chao, C., Yang, W., Yeh, T., Kan, Y., Wang, Y., Lee, K.-J., Hu, C.-J., Tang, T., Ide, T., Hsueh, H., et al. (2025) · Brain · doi:10.1093/brain/awaf028 · Cited by 9
Current trends in gene therapy to treat inherited disorders of the brain
Matuszek, Ż., Brown, B. L., Yrigollen, C. M., Keiser, M. S., & Davidson, B. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.057 · Cited by 14
Michieli, L. D., Lupi, A., Sinigiani, G., Tietto, A., Salvalaggio, A., Branca, A., Pozzo, S. D., Rizzo, S., Cecchin, D., Marra, M. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103481 · Cited by 10
“Gillmore et al. [76] have evaluated the safety and efficacy of in vivo CRISPR-Cas9 gene editing in humans with ATTRv with PN.”
CRISPR/Cas bioimaging: From whole body biodistribution to single-cell dynamics
Kolesova, E. P., Pulone, S., Kostyushev, D. S., & Tasciotti, E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115619 · Cited by 10
Challenges in Measuring In Vitro Activity of LNP-mRNA Therapeutics
Guerrini, G., Scaccabarozzi, D., Méhn, D., Sarracino, A., Gioria, S., & Calzolai, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178152 · Cited by 11
Hong, Y., Gan, S. K., & Shim, B. S. (2025) · Biomedical Engineering Letters · doi:10.1007/s13534-025-00511-6 · Cited by 19
“The safety and effectiveness of CRISPR-based treatments have been validated in human clinical trials, indicating their translational potential [136].”
Muscle-specific gene editing therapy via mammalian fusogen-directed virus-like particles
Zhou, S., Luo, J.-T., Chen, Y., Lu, Z.-D., Jian, Q.-H., Jiang, S.-Q., Li, J., Zhang, X., Tan, X., Yang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64200-9 · Cited by 10
“Nonetheless, the inability to target VLPs speci fi cally and effectively to skeletal muscles remains the main obstacle for this class of delivery vehicle 18 – 20 .”
ApoE2-DARPin fusion proteins enable selective RNA transfer to CD8 T cells by lipid nanoparticles
Theuerkauf, S. A., Zinser, L. J., Sheth, N., Adabi, E., Knapp, L. R., Gorol, J. M., Hein, S., Chroni, A., Thalheimer, F. B., & Buchholz, C. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114377 · Cited by 11
Marschhofer, M., Chen, S., Molbay, M., Winkeljann, B., Villano, E., Giancaspro, C., Kourou, A., Berninghausen, O., Rieder, S., Ungewickell, C., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114607 · Cited by 15
Innovations in CRISPR-Based Therapies
Kesavan, G. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00411-x · Cited by 7
“Indeed, a clinical trial using LNP-based delivery of gene editing components to the liver has been planned (NTLA2001, NCT04601051) [25].”
BackgroundCRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
Kostyushev, D. S., Kostyusheva, A. P., Ponomareva, N. I., Brezgin, S. A., & Chulanov, V. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0075 · Cited by 9
“Recently, CRISPR/Cas9 has been used to treat hereditary diseases in humans [108,109].”
Present and future of lipid nanoparticle-mRNA technology in phenylketonuria disease treatment
Díaz-Trelles, R., & Pérez‐García, C. G. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.008 · Cited by 10
Sellers, D. L., Lee, K., Murthy, N., & Pun, S. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.057 · Cited by 8
Case report: Magnetocardiography as a potential method of therapy monitoring in amyloidosis
Golpour, A., Suwalski, P., Landmesser, U., & Heidecker, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1224578 · Cited by 9
Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy
Brownell, D., Pillai, A. J., & Nair, N. (2023) · Current Cardiology Reviews · doi:10.2174/011573403x240302230925043500 · Cited by 11
“One of the potentially evolving strategies is in vivo gene editing [69-73].”
InfluentialKnauer, C., Haltern, H., Schoger, E., Kügler, S., Roos, L., Zelarayan, L. C., Hasenfuss, G. P., Zimmermann, W., Wollnik, B., & Cyganek, L. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102123 · Cited by 8
“14,15 Further, great translational progress has been made for CRISPR-based treatments of other congenital diseases, such as Duchenne muscular dystrophy and Progeria syndrome, 16 – 20 proven to be ef fi cient in patient-derived cells as well as mouse and large animal models.”
BackgroundSchneider, N., Steinberg, R., Ben-David, A., Valensi, J., David-Kadoch, G., Rosenwasser, Z., Banin, E., Levanon, E. Y., Sharon, D., & Ben‐Aroya, S. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102130 · Cited by 10
“9,10 However, in some cases, RNA editing could be a more appropriate alternative, as it does not require the introduction of foreign immunogenic prokaryotic proteins and any off-target effects are impermanent.”
BackgroundEngineering pluripotent stem cells with synthetic biology for regenerative medicine
Mao, Y., Wang, S., Yu, J., & Li, W. (2024) · Medical Review · doi:10.1515/mr-2023-0050 · Cited by 9
Chen, J., Su, S., Pickar‐Oliver, A., Chiarella, A. M., Hahn, Q., Goldfarb, D., Cloer, E. W., Small, G. W., Sivashankar, S., Ramsden, D. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae761 · Cited by 9
“…review), including Barth Syndrome ( 8 ), Duchenne Muscular Dystrophy ( 9 ,10 ), blindness ( 11 ), deafness ( 12 ), cancer ( 13 ), HIV infection ( 14 ), transthyretin amyloidosis ( 15 ), heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular diseases ( 16 ), and many others.”
BackgroundExploring RNA therapeutics for urea cycle disorders
Richard, E., Martínez‐Pizarro, A., & Desviat, L. R. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12807 · Cited by 11
“22,24”
Kidoh, M., Oda, S., Takashio, S., et al. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017427 · Cited by 8
Trachtenberg, B. H., Jiménez, J., Morris, A. A., Kransdorf, E. P., OWENS, A. T., Fishbein, D. P., Jordan, E., Kinnamon, D. D., Mead, J. O., Huggins, G. S., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.03.011 · Cited by 18
Genome Editing in Translational Medicine: An Inventory
Dobner, J., Ramachandran, H., & Rossi, A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708241 · Cited by 11
“Since liver cells are responsible for 99% of this protein’s production and genome editing resulted in up to 96% reduction of circulating protein, these results are very promising [94].”
BackgroundInfluentialCao, Y., Li, L., Ren, X., Mao, B., Yang, Y., Mi, H., Guan, Y., Li, S., Zhou, S., Guan, X., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4783 · Cited by 14
“Although it demonstrated beneficial effects in treating transthyretin amyloidosis,((52)) Parkinson’s disease,((53)) and serrated colorectal cancer,((54)) it has been associated with some off-target effects and safety concerns.”
BackgroundLipid nanoparticle-enabled gene editing in the lung via inhalation
(2023) · Nature Biotechnology · doi:10.1038/s41587-023-01689-9 · Cited by 8
Cancer Therapy Empowered by Extracellular Vesicle-Mediated Targeted Delivery
Chen, Y., Huang, Y., Deng, Y., Liu, X., Ye, J., Li, Q., Luo, Y., Lin, Y., Liang, R., Wei, J., et al. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00378 · Cited by 8
Large Serine Integrase Off-target Discovery and Validation for Therapeutic Genome EditingPreprint
Hazelbaker, D. Z., Mehta, J. B., McGinnis, C., Santesmasses, D., Bara, A. M., Liang, X., Biondi, T. C., Fennell, T. J., Homer, N., Estes, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.609471 · Cited by 11
“…or CD34+ hematopoietic stem and progenitor cells, as well as in vivo editing approaches that target the liver, require a two-step approach to first discover potential off-target sites and then validate sites with off-target edits through the detection off-target activity in edited cells 34, 37 .”
BackgroundMethodSelf-citationApplications of CRISPR technologies to the development of gene and cell therapy
Park, C.-S., Habib, O., Lee, Y.-S., & Hur, J. K. (2024) · BMB Reports · doi:10.5483/bmbrep.2023-0221 · Cited by 13
“In a clinical trial study by Gilmore et al , intravenous infusion of lipid nano particles (LNP) containing SpCas9 mRNA and sgRNA demonstrated notable therapeutic effect to trans-thyretin amyloidosis, a fatal disease caused by accumulating mis-folded transthyretin (TTR) proteins (58) (60).”
BackgroundAge-dependent small fiber neuropathy: Mechanistic insights from animal models
Taub, D. G., & Woolf, C. J. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114811 · Cited by 9
Unleashing the potential of mRNA : Overcoming delivery challenges with nanoparticles
Chen, Q., Huo, K.-G., Ji, S., Pang, S., Sun, T., Niu, Y., Jiang, Z., Zhang, P., Han, S., & Li, J. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10713 · Cited by 9
“For the treatment of transthyretin amyloidosis, sgRNA targeting the disease-causing TTR gene and mRNA sequences optimized for the spCas9 protein were delivered to the liver via LNP by Gillmore et al. 137 Clinical data showed that six patients were treated, with three receiving a 0.1 mg/kg dose and three receiving a 0.…”
InfluentialWang, X., Guo, T., Niu, L., Zheng, B., Huang, W., Xu, H., & Huang, W. (2024) · Oncogene · doi:10.1038/s41388-024-03136-8 · Cited by 7
“In vivo delivery of CRISPR to the liver using targeted lipid nanoparticles can selectively knockout TTR , to treat ATTR amyloidosis [71].”
Recent advances and applications of the CRISPR-Cas system in the gene therapy of blood disorders
Zanganeh, S., Zahedi, A. M., Bardsiri, M. S., Bazı, A., Bastanifard, M., Shool, S., Kouhbananinejad, S. M., Farsinejad, A., Afgar, A., Shahabi, A., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148865 · Cited by 8
Approved natural products-derived nanomedicines for disease treatment
Li, X., Yaoyao, L. A. I., Guanghan, W. A. N., Jiahui, Z. O. U., He, W., & Yang, P. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60726-0 · Cited by 23
Dimmeler, S., Ferri, L. D. A. F., Nioi, P., O’Donnell, C. J., Damy, T., Gómez‐Outes, A., Giacca, M., Guo, W., Kavousi, M., Kupatt, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf041 · Cited by 7
Lee, C., Lee, H. J., Jeong, S. H., & Lee, S. J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1575339 · Cited by 9
“This system is also used for genome editing in various organisms, including microbes (Shen et al., 2019), plants (Li et al., 2020), animals (Niu et al., 2014), and humans (Gillmore et al., 2021).”
Ferro, A., Segreti, A., Crispino, S. P., Cricco, R., Cristo, A. D., Ciancio, M., Gurrieri, F., Ussia, G. P., & Grigioni, F. (2025) · Genes · doi:10.3390/genes16070801 · Cited by 10
“At the same time, ethical considerations, such as concerns over germline editing and inequitable access, call for clear regulatory frameworks and open, patient-centered communication [131,136].”
Advances in the treatment of transthyretin amyloidosis
Anan, I. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100198 · Cited by 11
“70 Initially identified as part of bacterial immune defences against viral invasions, CRISPR-Cas9 has rapidly gained prominence as a versatile tool in laboratories globally.”
Discrete Immolative Guanidinium Transporters deliver mRNA to specific organs and red blood cells
Li, Z., Ee, A., Amaya, L., Hamad, J. L., Yadav, P. K., Wang, S. K., Chang, H. Y., & Wender, P. A. (2025) · Nature Communications · doi:10.1038/s41467-025-62200-3 · Cited by 9
Transthyretin cardiac amyloidosis: advances and ambiguities
Danilov, A., D’Angelo, L., Marsela, E., Costabel, J. P., Jorde, U. P., & Rochlani, Y. M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10552-9 · Cited by 9
Su, W.-C., Yu, Z., Lieu, R., Freund, E. C., Hokeness, K., Gu, Y., Kohler, J., Chen, T., Fan, Y., & Zhang, K. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466387 · Cited by 8
Chronic In Vivo CRISPR-Cas Genome Editing: Challenges, Long-Term Safety, and Outlook
Bao, C., Channell, C. I., Tseng, Y.-H., Bailey, J., Sbaiti, N., Demirkol, A., & Tsang, S. H. (2026) · Cells · doi:10.3390/cells15020156 · Cited by 18
“The trial began in 2020 and researchers reported interim 28-day results in 2021 and 12-month results in 2024 [55,136].”
Michael, A., Bhattacharya, D., Gopal, V., Suresh, D., Arun, J., & Ganesh, G. N. K. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2619919 · Cited by 10
“…being modified to target genetically determined subpopulations-such as LNp-mediated siRNA/CRISpR in transthyretin amyloidosis under the control of LDL-cholesterol genetic risk factors, and pCSK9-targeted LNps in hypercholesterolemia under the control of LDL-cholesterol genetic risk factors [138].”
Engineering the Future: Strategic Advances in Extracellular Vesicle-Mediated Drug Delivery Systems
Zhang, X., & Zhang, X. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s583242 · Cited by 13
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115019 · Cited by 10
Treating Cardiovascular Disease with Liver Genome Engineering
Hurley, A. E., & Lagor, W. R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00986-z · Cited by 7
Ascendancy of semi-synthetic biomaterials from design towards democratization
Speidel, A. T., Grigsby, C. L., & Stevens, M. M. (2022) · Nature Materials · doi:10.1038/s41563-022-01348-5 · Cited by 10
Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1
Costamagna, G., Govoni, A., Wise, A. H., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201294 · Cited by 7
“In addition, genome editing with mRNA CRISPR-Cas9 is being explored for Huntington disease(13) and hereditary transthyretin amyloidosis.(15)”
BackgroundHereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
Vélez-Santamaría, V., Nedkova-Hristova, V., de la Prida, M. M., & Casasnovas, C. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s338430 · Cited by 9
“In a phase I study conducted on patients with ATTRv-PN, NTLA-2001, the first systemically delivered CRISPR/Cas9 therapy, was well tolerated and reached a drop in TTR levels.(36)”
BackgroundEmerging therapeutic Avenues in cardiac amyloidosis.
Golatkar, V., & Bhatt, L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176142 · Cited by 6
Identifying technology clusters based on automated patent landscaping
Bergeaud, A., & Verluise, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295587 · Cited by 10
“He is the vice president in charge of research of Regeneron, a biotechnology company that develops different drugs and recently made important progress in new therapies using CRISPR [40].”
Advances in RNA therapeutics for modulation of ‘undruggable’ targets
Martinsen, E., Jinnurine, T., Subramani, S., & Rogne, M. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.003 · Cited by 7
Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy
Vaishnav, J., Brown, E. E., & Sharma, K. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.013 · Cited by 8
Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects
Singh, K., Bhushan, B., Kumar, S., Singh, S., Macadangdang, R. R., Pandey, E., Varma, A. K., & Kumar, S. (2024) · Current Gene Therapy · doi:10.2174/0115665232279528240115075352 · Cited by 11
Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applications
Sharrar, A. M., de Tacca, L. A., Meacham, Z. A., Staples-Ager, J., Collingwood, T. N., Rabuka, D., & Schelle, M. W. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105685 · Cited by 8
Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications
Sharrar, A. M., Meacham, Z. A., Staples-Ager, J., de Tacca, L. A., Rabuka, D., Collingwood, T. N., & Schelle, M. W. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0010 · Cited by 8
“9 A major hurdle for LNP therapies is the lack of tissue distribution, with most LNP formulations restricted to delivery to the liver.”
Lin, H., Lin, R., Hou, J., Zhu, C., Liu, G., Lin, Y., Su, J., Yang, M., Yang, B., Ma, Y., et al. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31291 · Cited by 9
“Gene therapy, a promising approach to treating human diseases, involves genetically modifying target cells to achieve therapeutic effects (Gillmore et al., 2021).”
Vilches, S., Martínez-Avial, M., Méndez, I., González, C. G., & Espinosa, M. A. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00667-9 · Cited by 7
“Of these six, four were men, the dose was adjusted by weight and the sample size was too small to draw conclusions about sex differences [59].”
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



